BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Reuters11-22
BRIEF-Lexicon To Reposition As Clinical Development-Focused Company Following Regulatory Update From FDA

Nov 22 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O:

  • LEXICON TO REPOSITION AS CLINICAL DEVELOPMENT-FOCUSED COMPANY FOLLOWING REGULATORY UPDATE FROM FDA

  • LEXICON PHARMACEUTICALS INC: EFFORTS EXPECTED TO REDUCE 2025 OPERATING COSTS BY $100 MILLION

  • LEXICON PHARMACEUTICALS INC: PRIORITIZING STRONG RESEARCH AND DEVELOPMENT PIPELINE INCLUDING ONGOING STUDIES IN DPNP, HCM AND OBESITY

  • LEXICON PHARMACEUTICALS INC: IMPLEMENTING STRATEGIC RESTRUCTURING TO ELIMINATE COMMERCIAL ORGANIZATION AND RATIONALIZE OPERATIONS ACROSS ALL FUNCTIONS

  • LEXICON PHARMACEUTICALS INC: TOTAL REDUCTION OF APPROXIMATELY 60 PERCENT OF EMPLOYEES, EFFECTIVE FOR MOST AFFECTED EMPLOYEES BY DECEMBER 31

  • LEXICON PHARMACEUTICALS INC: ELIMINATION OF PROMOTIONAL EFFORTS FOR INPEFA, PLANNED COMMERCIAL ACTIVITIES FOR ZYNQUISTA

  • LEXICON PHARMACEUTICALS INC: RECEIPT OF A "DEFICIENCIES PRECLUDE DISCUSSION" LETTER FROM FDA REGARDING NDA FOR ZYNQUISTA

Source text: ID:nGNXnl2zP

Further company coverage: LXRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment